Mineralys Therapeutics MLYS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$14.14M (3 inflow days, 17 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 36.4% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 10.91% to 8.70% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Capital Research | Mutual Fund | 2026/Q3 | +573,525 | 2.9% |
| BlackRock | Mutual Fund | 2026/Q3 | +285,115 | 7.0% |
| abrdn plc | Mutual Fund | 2026/Q3 | +243,123 | 1.1% |
| American Century Investment Management | Mutual Fund | 2026/Q3 | +235,297 | 1.4% |
| Deerfield Management Company, L.P. | Hedge Fund | 2026/Q3 | +3,958,000 | 4.5% |
| Capital Research | Mutual Fund | 2026/Q3 | +1,599,428 | 2.3% |
| BlackRock | Mutual Fund | 2026/Q3 | +1,405,456 | 6.7% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,205,696 | 4.7% |
| Ghisallo Capital Management LLC | Hedge Fund | 2026/Q3 | +1,125,000 | 1.3% |
| Troluce Capital Advisors, LLC | Mutual Fund | 2026/Q3 | +1,073,753 | 2.0% |
| Logos Global Management, L.P. | Hedge Fund | 2026/Q3 | +1,050,000 | 1.2% |
| Invesco Ltd. | Mutual Fund | 2026/Q3 | +1,046,753 | 1.2% |
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +919,163 | 2.6% |
| Millennium Management LLC | Hedge Fund | 2026/Q3 | +696,498 | 1.4% |
| abrdn plc | Mutual Fund | 2026/Q3 | +689,235 | 0.8% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 18 Oct 2026 | Kristine Peterson | Director | Other Acquisition | +12,400 | – | 12,400 |
| 18 Oct 2026 | Kristine Peterson | Director | Other Derivative Acquisition | +16,600 | $20.92 | 16,600 |
| 18 Oct 2026 | Lonnel Coats | Director | Other Acquisition | +12,400 | – | 12,400 |
| 18 Oct 2026 | Lonnel Coats | Director | Other Derivative Acquisition | +16,600 | $20.92 | 16,600 |
| 12 Oct 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -3,542 | $22.04 | – |
| 29 Sep 2026 | Jon Congleton | Chief Executive Officer | Automatic Disposition | -75,000 | $25.46 | 387,721 |
| 21 Sep 2026 | Catalys Pacific | Open Market Disposition | -104,320 | $28.81 | 7,799,518 | |
| 20 Sep 2026 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $28.12 | 38,400 |
| 16 Sep 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -417 | $27.95 | – |
| 14 Sep 2026 | Daphne Karydas | Independent Director | Derivative Exercise and Sale | -3,000 | $28.58 | 6,200 |
| 13 Sep 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -7,709 | $28.14 | – |
| 8 Sep 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -2,171 | $30.87 | – |
| 20 Aug 2026 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,437 | $25.98 | 38,400 |
| 16 Aug 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -417 | $25.46 | – |
| 12 Aug 2026 | David Rodman | Former Chief Medical Officer | Intent to Sell (Form 144) | -14,056 | $26.48 | – |
| 9 Aug 2026 | James Ferguson | Chief Medical Officer | Other Acquisition | +102,400 | – | 102,400 |
| 9 Aug 2026 | James Ferguson | Chief Medical Officer | Other Derivative Acquisition | +135,000 | $27.38 | 135,000 |
| 9 Aug 2026 | David Rodman | Former Chief Medical Officer | Derivative Exercise and Sale | -2,170 | $27.09 | 12,984 |
| 20 Jul 2026 | Eric Warren | Chief Commercial Officer | Derivative Exercise and Sale | -7,438 | $26.87 | 38,400 |
| 16 Jul 2026 | David Rodman | Former Chief Medical Officer | Derivative Exercise and Sale | -416 | $26.53 | 12,984 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 7,687,327 | 8.7% | 5.0 |
| 15 Oct 2026 | 7,438,452 | 8.4% | 5.3 |
| 30 Sep 2026 | 7,805,612 | 8.8% | 5.2 |
| 15 Sep 2026 | 9,181,891 | 10.4% | 6.4 |
| 31 Aug 2026 | 9,332,307 | 10.6% | 11.4 |
| 14 Aug 2026 | 9,645,951 | 10.9% | 13.0 |
No comments yet — be the first to weigh in on MLYS.
Sign in to join the discussion.